Clobetasol

# Clobetasol ## Overview - **Classification**: Potent (Class I) topical corticosteroid. - **Mechanism**: Binds to glucocorticoid receptors, inhibiting phospholipase A2. This reduces the synthesis of inflammatory mediators like prostaglandins and leukotrienes, suppressing inflammation, itching, and vasoconstriction. ## Primary Indications 1. **Severe Psoriasis** - Short-term management of moderate to severe plaque psoriasis. 2. **Severe Eczema/Dermatitis** - Treatment of severe, recalcitrant inflammatory dermatoses. 3. **Lichen Planus** - Management of severe lichen planus. ## Adult Dosing ### Standard Dosing **Severe Psoriasis/Eczema/Dermatitis/Lichen Planus** - **Dose**: Apply a thin layer of **0.05% cream, ointment, gel, or solution**. - **Frequency**: **Once or twice daily**. - **Route**: Topically to affected skin areas. - **Duration**: Treatment should not exceed **2 consecutive weeks**. - **Maximum**: Do not exceed **50 grams per week**. ### Dose Adjustments - **Renal Impairment**: No specific adjustments, as systemic absorption is minimal. - **Hepatic Impairment**: No specific adjustments, as systemic absorption is minimal. - **Elderly Patients**: Use with caution. Elderly skin may be thinner, increasing systemic absorption risk. Use lowest effective dose for shortest duration. ## Pediatric Dosing ### Neonates (0-28 days) - **Contraindicated**: High risk of systemic absorption and HPA axis suppression. - **Special Notes**: Infants and young children are more susceptible to systemic toxicity due to a higher skin surface area to body weight ratio. ### Infants (1-12 months) - **Contraindicated**: High risk of systemic absorption and HPA axis suppression. - **Special Notes**: Increased risk of Cushing's syndrome and growth retardation. ### Children (1-12 years) - **Contraindicated**: Per product labeling, clobetasol is **contraindicated in children under 12 years of age**. - **Special Notes**: High potential for systemic effects including HPA axis suppression, Cushing's syndrome, and growth retardation. If used off-label by expert discretion, use for very limited areas and duration (**<5-7 days**). Avoid occlusive dressings. ### Adolescents (13-18 years) - **Dose**: Similar to adult dosing, apply a thin layer of **0.05% cream, ointment, gel, or solution**. - **Frequency**: **Once or twice daily**. - **Maximum**: Do not exceed **50 grams per week** or **2 consecutive weeks**. - **Special Notes**: Use with caution. Monitor closely for signs of HPA axis suppression. Use lowest effective dose for shortest duration. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to clobetasol or other corticosteroids. - **Absolute**: Rosacea, perioral dermatitis, acne vulgaris. - **Absolute**: Pruritus without inflammation. - **Absolute**: Pediatric patients **<12 years old** (for most formulations). - **Absolute**: Untreated fungal, bacterial, or viral skin infections. ### Common Adverse Effects - **Very Common (>10%)**: Burning, stinging, itching at application site. - **Common (1-10%)**: Skin atrophy, telangiectasia, striae, dryness, folliculitis, hypertrichosis. - **Serious but Rare**: Adrenal suppression (HPA axis suppression), Cushing's syndrome, hyperglycemia, growth retardation (in children), allergic contact dermatitis. ### Key Drug Interactions - **CYP3A4 Inhibitors (e.g., ritonavir, itraconazole)**: May increase systemic exposure of clobetasol, increasing risk of systemic side effects. Use with caution. - **Other Topical Corticosteroids**: Avoid concomitant use; increases systemic absorption and local adverse effects. ## Monitoring & Follow-up - **Before Treatment**: Baseline assessment of skin condition, area, and severity of disease. - **During Treatment**: Monitor for signs of skin atrophy, infection, and HPA axis suppression (e.g., fatigue, weakness). Periodically reassess need for continued therapy. - **Clinical Signs**: Watch for skin thinning, bruising, striae, telangiectasias, signs of infection, or lack of efficacy. ## Clinical Pearls - 💡 **Tip 1**: Clobetasol is a very potent corticosteroid. Use for **short durations only** (max 2 weeks total per course) to minimize systemic and local side effects. - 💡 **Tip 2**: Advise patients to apply a **thin layer** to affected areas only. Do not use on face, groin, or axillae unless specifically directed by a physician due to increased absorption and higher risk of adverse effects. - 💡 **Tip 3**: Avoid **occlusive dressings** (e.g., bandages, tight clothing) over treated areas, as this significantly enhances systemic absorption and increases side effect risk. - 💡 **Tip 4**: Wash hands thoroughly after application unless the hands are the area being treated. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.